To amend title 38, United States Code, to direct the Secretary of Veterans Affairs to report on whether the Secretary will include certain psychedelic drugs in the formulary of the Department of Veterans Affairs.

Bill: 118-hr-7347
Sponsor: full_name: Rep. Van Orden, Derrick [R-WI-3]
Introduced: 2024-02-14
Policy area: Armed Forces and National Security
Subjects: Alternative treatments

Congressional oversight

Drug safety, medical device, and laboratory regulation

Drug trafficking and controlled substances

Prescription drugs
Latest action: action_date: 2024-09-06
text: Placed on the Union Calendar, Calendar No. 544.

Summaries:
action_date: 2024-02-14
action_desc: Introduced in House
text: <p>This bill requires the Department of Veterans Affairs (VA), when a psychedelic drug is approved or licensed by the Food and Drug Administration, to report on the VA's decision whether to include the drug in its formulary and the justification for such decision.</p>

tv_txt: IB Union Calendar No. 544 118th CONGRESS 2d Session H. R. 7347 [Report No. 118–647] IN THE HOUSE OF REPRESENTATIVES February 14, 2024 Mr. Van Orden introduced the following bill; which was referred to the Committee on Veterans' Affairs September 6, 2024 Additional sponsor: Mr. Bergman September 6, 2024 Committed to the Committee of the Whole House on the State of the Union and ordered to be printed A BILL To amend title 38, United States Code, to direct the Secretary of Veterans Affairs to report on whether the Secretary will include certain psychedelic drugs in the formulary of the Department of Veterans Affairs.

1. Reporting of determination of the Secretary of Veterans Affairs whether to include newly approved or licensed psychedelic drugs in the formulary of the Department of Veterans Affairs Chapter 81 of title 38, United States Code, is amended by inserting, after section 8125, the following new section (and conforming the table of sections at the beginning of such chapter accordingly): 8125A. Reporting of determination whether to include newly approved or licensed psychedelic drugs in the formulary of the Department Not later than 180 days after a psychedelic drug is approved under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) or licensed under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ), the Secretary shall submit to the Committees on Veterans’ Affairs of the Senate and House of Representatives a report regarding such drug, that includes— (1) the determination of the Secretary whether to include such drug in the formulary of the Department; and (2) the justification of the Secretary for such determination. .

September 6, 2024 Committed to the Committee of the Whole House on the State of the Union and ordered to be printed

tv_txt: I 118th CONGRESS 2d Session H. R. 7347 IN THE HOUSE OF REPRESENTATIVES February 14, 2024 Mr. Van Orden introduced the following bill; which was referred to the Committee on Veterans' Affairs A BILL To amend title 38, United States Code, to direct the Secretary of Veterans Affairs to report on whether the Secretary will include certain psychedelic drugs in the formulary of the Department of Veterans Affairs.

1. Reporting of determination of the Secretary of Veterans Affairs whether to include newly approved or licensed psychedelic drugs in the formulary of the Department of Veterans Affairs Chapter 81 of title 38, United States Code, is amended by inserting, after section 8125, the following new section (and conforming the table of sections at the beginning of such chapter accordingly): 8125A. Reporting of determination whether to include newly approved or licensed psychedelic drugs in the formulary of the Department Not later than 180 days after a psychedelic drug is approved under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) or licensed under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ), the Secretary shall submit to the Committees on Veterans’ Affairs of the Senate and House of Representatives a report regarding such drug, that includes— (1) the determination of the Secretary whether to include such drug in the formulary of the Department; and (2) the justification of the Secretary for such determination. .